ATLANTA — The remarkable ability of CAR-T therapies to eradicate cancer cells from desperately ill patients does not come without serious safety risks, notably the inflammatory storm called cytokine release syndrome and neurological side effects, including confusion and swelling of the brain. Currently, CAR-T therapy is administered in the hospital so admitted patients can be monitored closely for any warning signs. This adds costs to the already expensive treatment.

It also raises a key question: As CAR-T therapy evolves, will it ever become safe enough so patients can be treated and cared for outside the hospital?

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy